Two-Pronged attack tested against Tough-to-Treat cancers
NCT ID NCT03526679
Summary
This study tested the safety and effectiveness of combining two drugs, lenvatinib and eribulin, for people with advanced liposarcoma or leiomyosarcoma that could not be removed by surgery or had spread. The trial involved 30 participants whose cancer had progressed after up to two prior rounds of chemotherapy. Researchers aimed to see if using a drug that starves tumors of blood supply (lenvatinib) together with a chemotherapy (eribulin) could better control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan
Conditions
Explore the condition pages connected to this study.